{"nctId":"NCT01451398","briefTitle":"Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2011-11"},"conditions":["Type 2 Diabetes"],"count":353,"armGroups":[{"label":"TI inhalation powder","type":"EXPERIMENTAL","interventionNames":["Drug: Technosphere® Insulin"]},{"label":"Technosphere powder","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Technosphere Powder"]}],"interventions":[{"name":"Technosphere® Insulin","otherNames":[]},{"name":"Technosphere Powder","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HbA1c \\> or = to 7.5% and \\< or = to 10.0%\n* Body mass index (BMI) \\< or = to 45 kg/m2\n* Non smoker for at least 6 months before Screening\n* Clinical diagnosis of type 2 diabetes mellitus for more than 12 months\n* Currently receiving as diabetes treatment only metformin or 2 or more OADs and on stable doses for at least 3 months before enrollment\n\n  * Subjects receiving metformin must be on at least 1.5gm daily, or up to the maximum tolerated dose\n  * Subjects treated with a sulfonylurea must be on at least 50% of the total maximum approved dose for a given agent\n  * Subjects receiving a DPP-4 inhibitor must receive the maximum approved dose specific for that agent\n  * Metiglinide and alpha-glucoside inhibitors must be taken at the highest tolerated dose within the approved dose range\n* No previous or current treatment with insulin, except during an acute illness, gestational diabetes, or at time of initial diagnosis of diabetes\n* Forced expiratory volume in one second (FEV1) \\> or = to 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted\n* Forced vital capacity (FVC) \\> or = to 70% NHANES III predicted\n* Forced expiratory volume in one second as a percentage of forced vital capacity (FEV1/FVC) \\> or = to NHANES III lower limit of normal (LLN)\n\nExclusion Criteria:\n\n* History of chronic obstructive pulmonary disease (COPD), clinically proven asthma, or any other clinically important pulmonary disease (eg, pulmonary fibrosis)\n* Any clinically significant radiological findings on screening chest x-ray\n* Use of medications for asthma, COPD, or any other chronic respiratory conditions\n* Evidence of serious complications of diabetes (proliferative retinopathy, autonomic neuropathy with symptoms of gastroparesis or cardiac arrhythmia; sensory neuropathy that makes manipulation of the Gen2C inhaler difficult)\n* Renal disease or renal dysfunction\n* Significant cardiovascular dysfunction or history thereof within 12 months of screening; serious arrhythmia, treatment with medications to control/treat arrhythmias; myocardial infarction; cardiac surgery; history of valvular heart disease\n* Previous or current use of amiodarone\n* Treatment with glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones (TZD), or weight loss drugs (eg, sibutramine, orlistat) within 3 months of screening\n* History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening\n* History of recent blood transfusion (within previous 3 months) or diagnosis of hemoglobinopathies that may affect HbA1c measurements","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 24 in HbA1c","description":"Efficacy as measured by change in glycated hemoglobin (HbA1c) at Week 24","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.82","spread":"0.061"},{"groupId":"OG001","value":"-0.42","spread":"0.062"}]}]}]},{"type":"SECONDARY","title":"Proportion of Responders Achieving HbA1c <= 7.0%","description":"Efficacy as measured in proportion of subjects achieving HbA1c \\< or = to 7.0%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null},{"groupId":"OG001","value":"19.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Responders Achieving HbA1c <= 6.5%","description":"Efficacy as measured in proportion of subjects achieving HbA1c \\< or = to 6.5% at Week 24","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline to Week 24","description":"Efficacy as measured by mean change in fasting plasma glucose (FPG)","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.20","spread":"3.776"},{"groupId":"OG001","value":"-3.78","spread":"3.864"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Requiring Rescue Therapy","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Rescue","description":"Time from Week 0 (baseline) to initiation of rescue therapy (up to a maximum of 24 weeks/end of treatment) for subjects not responding to treatment","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"FEV1 Change From Baseline to Week 24","description":"Forced Expiratory Volume in 1 second - change from baseline to week 24","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.175"},{"groupId":"OG001","value":"-0.04","spread":"0.147"}]}]}]},{"type":"SECONDARY","title":"Incidence of Total Hypoglycemia","description":"Hypoglycemia, defined as blood glucose \\<= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":null},{"groupId":"OG001","value":"30.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Severe Hypoglycemia","description":"Severe Hypoglycemia defined as: Requiring 3rd party assistance.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Hypoglycemia Event Rate","description":"Number of Hypoglycemic Events/Total Subject Exposure Time (in months)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":null},{"groupId":"OG001","value":"0.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Severe Hypoglycemia Event Rate","description":"Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":null},{"groupId":"OG001","value":"0.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean 7-point Glucose Baseline Values","description":"Mean 7-point self-monitored glucose at baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178.5","spread":"37.58"},{"groupId":"OG001","value":"182.2","spread":"40.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212.8","spread":"51.01"},{"groupId":"OG001","value":"219.9","spread":"51.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176.7","spread":"49.58"},{"groupId":"OG001","value":"183.6","spread":"53.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197.0","spread":"46.94"},{"groupId":"OG001","value":"209.1","spread":"44.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"176.8","spread":"41.81"},{"groupId":"OG001","value":"187.6","spread":"50.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205.2","spread":"48.72"},{"groupId":"OG001","value":"211.2","spread":"50.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203.3","spread":"50.55"},{"groupId":"OG001","value":"203.8","spread":"46.52"}]}]}]},{"type":"SECONDARY","title":"Mean 7-point Glucose Week 24 Values","description":"Mean 7-point self-monitored blood glucose at Week 24","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156.6","spread":"30.80"},{"groupId":"OG001","value":"160.9","spread":"36.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170.3","spread":"44.23"},{"groupId":"OG001","value":"194.7","spread":"50.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152.4","spread":"48.13"},{"groupId":"OG001","value":"163.4","spread":"49.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158.0","spread":"42.79"},{"groupId":"OG001","value":"183.8","spread":"47.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"157.4","spread":"49.34"},{"groupId":"OG001","value":"164.7","spread":"40.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164.3","spread":"44.84"},{"groupId":"OG001","value":"188.5","spread":"43.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163.0","spread":"42.66"},{"groupId":"OG001","value":"178.7","spread":"44.50"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 24","description":"Change in body weight from Baseline to Week 24","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"0.333"},{"groupId":"OG001","value":"-1.13","spread":"0.347"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":177},"commonTop":["Cough","Nasopharyngitis","Upper Respiratory Tract Infection","Influenza","Oropharyngeal Pain"]}}}